Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merck's Keytruda, which previously showed promising results in reducing recurrence risk. Moderna's small revenue base means the trial results could cause significant stock volatility. The company and partner Merck will present detailed findings, followed by a Moderna investor webcast, with the market closely watching for confirmation of earlier positive outcomes.
Moderna's stock is up 6.19% on Pluang as of Oct 21, 2026 01:02 WIB, trading at USD 240.94. Bristol-Myers Squibb shares have risen 4.86% to USD 61.69, while Pfizer is up 2.72% at USD 30.24. The market shows strong buying interest in Moderna with 66% of orders as buys, contrasting with Bristol-Myers Squibb's 100% sell orders.
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
